137975-27-0

Basic information

• Product Name: 2H-1,4-Benzoxazine, 3,4-dihydro-4-(4-nitrobenzoyl)-
• CAS NO: 137975-27-0
• Molecular Formula: C15H12N2O4
• Molecular Weight: 284.271
• Mol File: 137975-27-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2H-1,4-Benzoxazine, 3,4-dihydro-4-(4-nitrobenzoyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-1,4-Benzoxazine, 3,4-dihydro-4-(4-nitrobenzoyl)-(137975-27-0)
• EPA Substance Registry System: 2H-1,4-Benzoxazine, 3,4-dihydro-4-(4-nitrobenzoyl)-(137975-27-0)

Safety Data

• Hazardous Substances Data: 137975-27-0(Hazardous Substances Data)

Upstream product

• 888730-46-9 (3-chloro-4-hydroxyphenyl)-(2,3-dihydrobenzo[1,4]oxazin-4-yl)-methanone 
• 5735-53-5 1,4-benzoxazine 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 137975-48-5 (4-Amino-phenyl)-(2,3-dihydro-benzo[1,4]oxazin-4-yl)-methanone 

Relevant articles and documents

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Orally active, nonpeptide vasopressin V2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds

This paper describes a novel series of nonpeptide vasopressin V2 receptor antagonists. It has been demonstrated that the 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-benzazepines and 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-1,5-benzodiazepines show a high affinity for V2 (and V(1a)) receptors. Among the 1-[4-(benzoylamino)benzoyl]-2,3,4,5- 1H-benzazepine series, compounds with an alkylamino group on the benzazepine ring have been shown to have oral activity. A lipophilic group at the ortho position on the terminal benzoyl ring is important for both high V2 receptor affinity and oral activity. On the basis of these favorable properties, clinical testing of 31b has begun for use as an oral and iv aquaretic agent.